Drug intelligence / Profile preview

triamcinolone acetonide + miconazole + neomycin

Development stage
Unknown
Lead developer
Hubei Kangzheng Pharmaceutical
Modality
Small Molecules
Administration
Topical
01

Overview

This drug is a topical combination therapy developed by Hubei Kangzheng Pharmaceutical, containing triamcinolone acetonide, miconazole nitrate, and neomycin sulfate. It is specifically formulated for the treatment of mixed bacterial and fungal skin infections that are accompanied by significant inflammation. Triamcinolone acetonide is a potent synthetic corticosteroid that provides anti-inflammatory, antipruritic, and vasoconstrictive effects by activating glucocorticoid receptors. Miconazole is an imidazole antifungal agent that works by inhibiting the synthesis of ergosterol, thereby disrupting fungal cell membrane integrity. Neomycin is an aminoglycoside antibiotic that targets bacterial protein synthesis by binding to the 30S ribosomal subunit. This triple-action approach allows for the simultaneous management of infection and the symptomatic relief of associated skin irritation.

Brand names
复方曲安奈德/咪康唑/新霉素乳膏
Other names
Compound Triamcinolone Acetonide, Miconazole and Neomycin CreamTriamcinolone acetonide, miconazole nitrate and neomycin sulfate cream
02

Targets

30S A-site (Bacterial ribosomal 30S A-site)GR (Glucocorticoid receptor)CYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on triamcinolone acetonide + miconazole + neomycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on triamcinolone acetonide + miconazole + neomycin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call